Nippon Shokubai and GlyTech Announce to Collaborate on R&D and Nippon Shokubai Subscribe for Shares of GlyTech through Third Party Allotment

NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Japan, President: Masanori Ikeda, hereinafter “Nippon Shokubai”) and GlyTech, Inc. (Headquarter: Kyoto, Japan, President: Hiroaki Asai, hereinafter “GlyTech”) announce that they have agreed to collaborate on research and development of Glycosylated Somatostatin Analog (hereinafter “G-SRIF”). Based on this agreement with GlyTech, Nippon Shokubai has decided to establish a laboratory of peptide API (active pharmaceutical ingredient) synthesis.

GlyTech and Nippon Shokubai announce that they have decided to subscribe for shares of GlyTech to Nippon Shokubai through a third party allotment.

For further information, please see the following file.